Tetraphase Spikes on Encouraging Data on Antibiotic - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 19, 3:19PM CST
Tetraphase Pharmaceuticals, Inc. announced positive top-line data from a phase III study evaluating eravacycline for the treatment of complicated intra-abdominal infection.
JNJ: 104.59 (+0.31), TTPH: 38.86 (+0.53), CBST: 100.29 (-0.09), MRK: 57.46 (+0.25)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Dec 18, 11:47AM CST
NETE: 1.20 (unch), TTPH: 38.86 (+0.53), NES: 4.96 (-0.44), OVAS: 43.73 (+3.22), MCEP: 6.07 (-0.12), FMD: 5.06 (unch), ISIG: 3.78 (+0.02), WOR: 30.41 (+0.34), IMNP: 1.89 (+0.02), GLRI: 4.20 (+0.16), MBT: 8.11 (+0.06), NDRO: 4.84 (-0.05), OBCI: 4.55 (+0.03), INS: 1.56 (-0.01), SIMG: 5.31 (-0.07), KEG: 1.73 (+0.01), MPO: 1.63 (-0.05), TRXC: 2.79 (+0.03), CRK: 7.01 (-0.20), ZAGG: 6.66 (+0.13)
Tetraphase Jumps As 'Superbug' Drug Scores In Trial
at Investor's Business Daily - Thu Dec 18, 10:54AM CST
Biotech Tetraphase Pharmaceuticals (TTPH) jumped 16% to a new high Thursday and got a volley of price target increases after it reported positive trial results for its antibiotic late Wednesday. The trial found Tetraphase's eravacycline to be...
TTPH: 38.86 (+0.53), ACT: 254.20 (-1.68), CBST: 100.29 (-0.09), MRK: 57.46 (+0.25)
Taking Wall Street by Storm: Special Coverage on Tetraphase, Oracle, Jabil, Paramount and Target
PR Newswire - Thu Dec 18, 8:28AM CST
Moments ago, Realtime Equities released new analyst updates concerning several important developing situations including Tetraphase (NASDAQ: TTPH), Oracle (NYSE: ORCL), Jabil (NYSE: JBL), Paramount (NYSE MKT: PZG), and Target (NYSE: TGT). Realtime Equities is the leader in realtime news, commentary and analysis - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
TTPH: 38.86 (+0.53), PZG: 1.00 (+0.06), TGT: 74.65 (-0.04), JBL: 21.88 (+0.17), ORCL: 46.23 (+0.22)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Thu Dec 18, 8:14AM CST
VIP: 4.07 (-0.26), TTPH: 38.86 (+0.53), FRO: 2.43 (-0.01), EXXI: 3.45 (-0.22), OVAS: 43.73 (+3.22), EOX: 1.33 (+0.05), NVGN: 2.40 (-0.09), WLT: 1.45 (-0.02), AKS: 5.76 (+0.11), MBT: 8.11 (+0.06), NADL: 1.68 (-0.08), NQ: 4.32 (-0.36), RVLT: 1.28 (-0.02), SSE: 6.64 (-0.03), AREX: 6.98 (-0.11), RAD: 7.26 (-0.09), AGEN: 3.85 (unch), PBR: 7.60 (-0.11), DNKN: 41.85 (-0.13), GDP: 4.93 (-0.22), SIMG: 5.31 (-0.07), KEG: 1.73 (+0.01), LINE: 10.93 (-0.32)
Market Maker Surveillance Report. SFY, NES, GASL, MDBX, TTPH, XNCR, Winning Stocks With Lowest Price Friction For Wednesday, December 17th 2014
M2 - Thu Dec 18, 12:56AM CST
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 4931 companies with "abnormal" market making, 4995 companies with positive Friction Factors and 2119 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Wednesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Swift Energy Co (NYSE:SFY), M/S GBCPN 3 GBL INDS (NYSE:NES), Direxion Daily Natural Gas Related Bull 2x Shares (NYSE:GASL), (OTC:MDBX), (NASDAQ:TTPH), (NASDAQ:XNCR). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
TTPH: 38.86 (+0.53), GASL: 4.67 (-0.22), NES: 4.96 (-0.44), SFY: 4.47 (-0.06), XNCR: 16.83 (+0.77)
TETRAPHASE PHARMA
at Investor's Business Daily - Wed Dec 17, 5:50PM CST
TETRAPHASE PHARMA (TTPH) rose 14.5% to 37.99 after unveiling positive phase 3 trial results on eravacycline for treating intra-abdominal infections. The developer of antibiotics for resistant infections had closed up 10.6% to 33.19, a new high.
TTPH: 38.86 (+0.53)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 4:40PM CST
E: 36.10 (-0.25), TTPH: 38.86 (+0.53), RCAP: 11.23 (+0.26), PKD: 3.11 (+0.03), RUSS: 24.00 (-2.60), GTI: 4.84 (-0.04), AKS: 5.76 (+0.11), REI: 10.95 (+0.22), ORCL: 46.23 (+0.22), ZAGG: 6.66 (+0.13)
Tetraphase antibiotic non-inferior to ertapenem in Phase 3 study
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 3:44PM CST
TTPH: 38.86 (+0.53)
Tetraphase Announces Positive Top-line Results from Phase 3 IGNITE 1 Clinical Trial of Eravacycline in Complicated Intra-abdominal Infections
Business Wire - Wed Dec 17, 3:01PM CST
----Company to host conference call at 4:30 p.m. ET today -
TTPH: 38.86 (+0.53)
3 Momentum Stocks Undeterred by a Shaky Market - Analyst Blog
Sweta Killa - Zacks Investment Research - Tue Dec 16, 10:04AM CST
These stocks look to be a great play when the market has been trapped in the vicious circle of oil trading.
PTRY: 36.78 (+0.28), TTPH: 38.86 (+0.53), BBW: 19.35 (+0.25)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), FPRX: 26.12 (+0.07), ZFGN: 30.99 (+0.67), CRIS: 1.29 (+0.04), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)
Tetraphase Pharmaceuticals Added to NASDAQ Biotechnology Index
Business Wire - Mon Dec 15, 7:18AM CST
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing novel antibiotics for serious and life-threatening multidrug-resistant (MDR) bacterial infections, today announced that it has been selected for addition to the NASDAQ Biotechnology Index(R) (Nasdaq:^NBI). The annual re-ranking of the NASDAQ Biotechnology Index will become effective upon market open on Monday, December 22, 2014.
TTPH: 38.86 (+0.53)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), ZGNX: 1.20 (+0.04), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), NDAQ: 48.74 (-0.40), FPRX: 26.12 (+0.07), CRIS: 1.29 (+0.04), ZFGN: 30.99 (+0.67), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)
Inogen Leases Texas Facility, Lower Costs to Drive Growth - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 12, 11:20AM CST
Inogen Inc (INGN) recently agreed to lease approximately 23,890 square feet area in Richardson, TX.
TTPH: 38.86 (+0.53), PHG: 29.39 (-0.06), IVC: 16.80 (+0.20), INGN: 29.99 (-0.09)
Community-Acquired Infections Global Clinical Trials Review, H2, 2014
M2 - Thu Dec 11, 6:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/hxr44r/communityacquired) has announced the addition of the "Community-Acquired Infections Global Clinical Trials Review, H2, 2014" report to their offering. Community-Acquired Infections Global Clinical Trials Review, H2, 2014" provides data on the Community-Acquired Infections clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Community-Acquired Infections. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Community-Acquired Infections. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - GlaxoSmithKline plc - Pfizer Inc. - Panacea Biotec Limited - Daiichi Sankyo Company, Limited - Tetraphase Pharmaceuticals Inc. - TaiGen Biopharmaceuticals Holdings Limited - Janssen Research & Development, LLC - Dong Wha Pharma Co., Ltd. - Cubist Pharmaceuticals, Inc. - Belpharma S.A. Clinical Trial Overview of Top Institutes / Government - Hanyang University Medical Center - Ewha Womans University - Kyungpook National University - Katholieke Universiteit Leuven - Rennes University Hospital - University of Milan For more information visit http://www.researchandmarkets.com/research/hx...tyacquired About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
TTPH: 38.86 (+0.53), CBSTZ: 0.06 (+0.01), PFE: 31.42 (-0.03), GSK: 42.85 (+0.11)
Tetraphase Pharmaceuticals (TTPH) Jumps: Stock Up 8.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 09, 7:30AM CST
Tetraphase Pharmaceuticals, Inc. (TTPH) was a big mover last session, as the company saw its shares rise nearly 9% on the day.
LCI: 42.29 (+1.79), TTPH: 38.86 (+0.53), IG: 9.11 (-0.01), BIOD: 1.36 (-0.04)
Strong Portfolio, Dividends Make Merck An Attractive Opportunity
Kanak Kanti De - at Seeking Alpha - Mon Dec 08, 2:40PM CST
TTPH: 38.86 (+0.53), CBST: 100.29 (-0.09), MRK: 57.46 (+0.25), RTGN: 3.65 (+0.10)
Tetraphase Pharmaceuticals to Present at the Oppenheimer 25th Annual Healthcare Conference
Business Wire - Thu Dec 04, 6:00AM CST
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company whose lead product candidate, eravacycline, is being developed as a broad-spectrum intravenous and oral antibiotic designed to be effective against multidrug-resistant bacteria, today announced that Guy Macdonald, Tetraphase President and Chief Executive Officer, will present at the Oppenheimer 25th Annual Healthcare Conference on Thursday, December 11 at 1:00 p.m. Eastern Time. The conference will take place at the Crowne Plaza Hotel in New York.
TTPH: 38.86 (+0.53)
SCYNEXIS, Inc. Announces Appointment of Two Seasoned Industry Professionals to Its Board of Directors
GlobeNewswire - Wed Dec 03, 8:24AM CST
SCYNEXIS, Inc. (Nasdaq:SCYX) today announced the appointment of Guy Macdonald and Marco Taglietti, M.D., to its Board of Directors. Mr. Macdonald currently serves as President and Chief Executive Officer of Tetraphase Pharmaceuticals, Inc., and Dr. Taglietti is former Executive Vice President of Research and Development and Chief Medical Officer of Forest Laboratories, Inc. In addition, the Company announced that Mounia Chaoui, Ph.D., has resigned from the Board of Directors.
TTPH: 38.86 (+0.53), SCYX: 10.49 (+0.65), FRX: 99.00 (-0.77)